---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-010354"
form_type: "8-K"
ticker: "AKTS"
cik: "0002035832"
company_name: "Aktis Oncology, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:58:33.163231+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aktis Oncology adopts classified board, supermajority vote, and eliminates written consent post-IPO

## Summary
- Filed amended charter authorizing 480M shares of common, 10M Class A common, and 10M undesignated preferred stock.
- Adopted classified board with staggered three-year terms; removal of directors requires two-thirds vote for cause.
- Eliminated stockholder action by written consent in lieu of meetings.
- Amended bylaws to establish procedures for stockholder proposals and director nominations.
- All changes effective Jan 12, 2026 in connection with IPO completion, as previously disclosed in S-1.

## SEC filing metadata
- accession: 0001193125-26-010354
- form_type: 8-K
- ticker: AKTS
- cik: 0002035832
- company_name: Aktis Oncology, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2035832/000119312526010354/0001193125-26-010354-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2035832/000119312526010354/d932945d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-010354
- JSON: https://secwatch.observer/filing/0001193125-26-010354.json
- Plain text: https://secwatch.observer/filing/0001193125-26-010354.txt

## Source-grounded claims
- claim_id: 196d34ba06752b22feffe1a8bc60d0f2bb5eb083
  claim: Aktis Oncology, Inc.: Amended and restated bylaws to establish procedures for stockholder proposals and director nominations, modify indemnification provisions, and conform to amended charter (effective 2026-01-12).
  evidence_excerpt: the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), became effective as of immediately prior to the completion of the IPO on January 12, 2026. The Amended and Restated Bylaws amend and restate the Company’s bylaws in their entirety to, among other things: (i) establish procedures relating to the presentation of stockholder proposals at stockholder meetings; (ii) establish procedures relating to the nomination of directors; (iii) modify the indemnification provisions for the Company’s directors and officers, and (iv) conform to the amended provisions of the Amended and Restated Certificate.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2035832/000119312526010354/0001193125-26-010354-index.htm
- claim_id: 6defbeaf19ec7063154f6dff122d4697f175a1c6
  claim: Aktis Oncology, Inc.: Amended and restated certificate of incorporation to authorize additional common/preferred stock, eliminate existing preferred series, change director removal vote threshold, establish classified board, and eliminate stockholder action by written consent (effective 2026-01-12).
  evidence_excerpt: on January 12, 2026, the Company filed its amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with the Secretary of State of the State of Delaware. The Amended and Restated Certificate amends and restates the Company’s existing sixth amended and restated certificate of incorporation, as amended, in its entirety to, among other things: (i) authorize 480,000,000 shares of Common Stock and 10,000,000 shares of Class A common stock, par value $0.0001 per share; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Company’s board of directors (the “Board”) in one or more series; (iv) require the approval of at least two-thirds of the shares entitled to vote to remove a director for cause; (v) establish a classified Board, as a result of which, the successors to the directors whose terms have expired will be elect
  evidence_url: https://www.sec.gov/Archives/edgar/data/2035832/000119312526010354/0001193125-26-010354-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.